Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Angiotension receptor blockers reduce the risk of dementia.

Chiu WC, Ho WC, Lin MH, Lee HH, Yeh YC, Wang JD, Chen PC; Health Data Analysis in Taiwan (hDATa) Research Group.

J Hypertens. 2014 Apr;32(4):938-47. doi: 10.1097/HJH.0000000000000086.

PMID:
24406780
2.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.

Kuan YC, Huang KW, Yen DJ, Hu CJ, Lin CL, Kao CH.

Int J Cardiol. 2016 Oct 1;220:462-6. doi: 10.1016/j.ijcard.2016.06.215. Epub 2016 Jun 27.

PMID:
27390970
3.

Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population--a nationwide cohort study.

Hsu CY, Huang CC, Chan WL, Huang PH, Chiang CH, Chen TJ, Chung CM, Lin SJ, Chen JW, Leu HB.

Circ J. 2013;77(2):405-10. Epub 2012 Nov 10.

4.

Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis.

Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen TJ, Chiang CE.

Int J Cardiol. 2013 Sep 1;167(5):2162-6. doi: 10.1016/j.ijcard.2012.05.096. Epub 2012 Jun 17.

PMID:
22709730
5.

Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.

Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS.

Cardiovasc Diabetol. 2014 May 14;13:91. doi: 10.1186/1475-2840-13-91.

6.

Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.

Chiang YY, Chen KB, Tsai TH, Tsai WC.

J Clin Hypertens (Greenwich). 2014 Jan;16(1):27-33. doi: 10.1111/jch.12228. Epub 2013 Nov 8.

7.

Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.

Petrella R, Michailidis P.

Clin Ther. 2011 Sep;33(9):1190-203. doi: 10.1016/j.clinthera.2011.08.008. Epub 2011 Sep 1.

PMID:
21885126
8.

Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research Datalink.

Zhou EH, Gelperin K, Levenson MS, Rose M, Hsueh YH, Graham DJ.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):340-7. doi: 10.1002/pds.3549. Epub 2013 Nov 28.

PMID:
24285502
9.

Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias.

Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM.

J Alzheimers Dis. 2011;26(4):699-708. doi: 10.3233/JAD-2011-110347.

PMID:
21709373
10.

Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.

Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, Levenson M, Li L, McCloskey C, Shoaibi A, Wu E, Zornberg G, Hennessy S.

Arch Intern Med. 2012 Nov 12;172(20):1582-9. doi: 10.1001/2013.jamainternmed.34. Erratum in: Arch Intern Med. 2013 Jan 14;173(1):14.

PMID:
23147456
11.

Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus.

Johnson ML, Parikh N, Kunik ME, Schulz PE, Patel JG, Chen H, Aparasu RR, Morgan RO.

Alzheimers Dement. 2012 Sep;8(5):437-44. doi: 10.1016/j.jalz.2011.05.2414. Epub 2012 Apr 21.

PMID:
22521970
12.

Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy.

Mathes J, Kostev K, Gabriel A, Pirk O, Schmieder RE.

Int J Clin Pharmacol Ther. 2010 Mar;48(3):173-83.

PMID:
20197011
13.

Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.

Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.

JAMA Intern Med. 2014 Mar;174(3):347-54. doi: 10.1001/jamainternmed.2013.12700.

PMID:
24343093
14.

Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study.

Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS.

PLoS One. 2014 Jun 9;9(6):e98961. doi: 10.1371/journal.pone.0098961. eCollection 2014.

15.

Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database.

Park I, Sheen SS, Lim HS, Yoon D, Park MY, Lee SH, Shin GT, Kim H, Park RW.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):255-62. doi: 10.2165/11634470-000000000-00000.

PMID:
22799614
16.

Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.

Opelz G, Döhler B.

Transplantation. 2014 Feb 15;97(3):310-5. doi: 10.1097/01.TP.0000437672.78716.28.

PMID:
24492421
17.

Diverticular disease and additional comorbidities associated with increased risk of dementia.

Peng YC, Lin CL, Yeh HZ, Tung CF, Chang CS, Kao CH.

J Gastroenterol Hepatol. 2016 Nov;31(11):1816-1822. doi: 10.1111/jgh.13389.

PMID:
27029523
18.

Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers.

Graham DJ, Zhou EH, McKean S, Levenson M, Calia K, Gelperin K, Ding X, MaCurdy TE, Worrall C, Kelman JA.

Pharmacoepidemiol Drug Saf. 2014 Apr;23(4):331-9. doi: 10.1002/pds.3548. Epub 2013 Nov 26.

PMID:
24277678
19.

Hepatitis C viral infection and the risk of dementia.

Chiu WC, Tsan YT, Tsai SL, Chang CJ, Wang JD, Chen PC; Health Data Analysis in Taiwan (hDATa) Research Group.

Eur J Neurol. 2014 Aug;21(8):1068-e59. doi: 10.1111/ene.12317. Epub 2013 Dec 7.

PMID:
24313931
20.

Uptake of angiotensin II receptor blockers in the treatment of hypertension.

Greving JP, Denig P, van der Veen WJ, Beltman FW, Sturkenboom MC, de Zeeuw D, Haaijer-Ruskamp FM.

Eur J Clin Pharmacol. 2005 Jul;61(5-6):461-6. Epub 2005 May 24.

PMID:
15912393

Supplemental Content

Support Center